Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy

Molecular glue degraders (MGDs) are proximity-inducing agents that mediate the cooperative interaction between a target protein and an E3 ligase, introducing an additional layer of specificity beyond that afforded by traditional small molecules. Historically, molecular glues that stabilize protein–p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JACS Au Ročník 4; číslo 11; s. 4423 - 4434
Hlavní autoři: Huang, Lu, Chen, Lu, Peng, Bo, Zhou, Lixin, Sun, Yanli, Shi, Taiting, Lu, Jiayi, Lin, Weiye, Liu, Yuhang, Cao, Linhui, Li, Lanlan, Han, Qiangqiang, Chen, Xi, Yang, Ping, Zhang, Shuo, Wang, Zhe, Yang, Jing, Guo, Zhixiang, Jiang, Baishan, Lu, Wenchao
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States American Chemical Society 25.11.2024
Témata:
AML
molecular glue
degrader
CK1α
induced proximity
P53
ISSN:2691-3704, 2691-3704
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Molecular glue degraders (MGDs) are proximity-inducing agents that mediate the cooperative interaction between a target protein and an E3 ligase, introducing an additional layer of specificity beyond that afforded by traditional small molecules. Historically, molecular glues that stabilize protein–protein interactions were often discovered serendipitously. In this study, we leveraged the reprogramming potential of cereblon (CRBN)-based ligands and conducted a CRBN-dependent proliferation screen to identify CRBN-based MGDs capable of inducing the degradation of proteins essential for cell viability. Through our screening and subsequent medicinal chemistry optimization, we identified dCK1α-1 as a potent and selective CK1α-targeting molecular glue degrader. Furthermore, we synthesized an orally active derivative, dCK1α-2, with enhanced pharmacokinetic properties, which exhibited pronounced degradation activity and demonstrated efficacy in mouse models following oral gavage. These findings indicate that phenotypic drug discovery campaigns, in combination with chemically distinct CRBN ligand libraries, can accelerate the development of therapeutically relevant MGDs. Furthermore, the development of dCK1α-1 and dCK1α-2 provides new therapeutic options for cancers with functional p53 signaling and offers valuable chemical tools for future investigations into the role of CK1α.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2691-3704
2691-3704
DOI:10.1021/jacsau.4c00762